Cytokine and antibody profiles in 1-year-old children vaccinated with either acellular or whole-cell pertussis vaccine during infancy

Vaccine

Volumn 27, Issue 43, 2009, Pages 6042-6047

  Dirix, V ^a   Verscheure, V ^a   Goetghebuer, T ^b   Hainaut, M ^b   Debrie, A S ^c,d   Locht, C ^c,d   Mascart, F ^a,e  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^c INSERM   (France)

^d INSTITUT PASTEUR DE LILLE   (France)

^e ERASME HOSPITAL   (Belgium)

Author keywords

Antigen specific immune responses; Human infants; Pertussis vaccines

Indexed keywords

ACT HIB; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INFLUENZA VACCINE; INTERLEUKIN 13; INTERLEUKIN 5; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; RECOMBINANT HEPATITIS B VACCINE; TETANUS TOXOID; TETRAVAC; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BORDETELLA PERTUSSIS; CELLULAR IMMUNITY; CHILD; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIPHTHERIA; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA; MAJOR CLINICAL STUDY; PERTUSSIS; POLIOMYELITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DETERMINATION; T LYMPHOCYTE; TETANUS; TH1 CELL; TH2 CELL; VACCINATION;

ANTIBODIES, BACTERIAL; CELLS, CULTURED; CYTOKINES; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INFANT; LEUKOCYTES, MONONUCLEAR; PERTUSSIS VACCINE; TETANUS TOXOID; TH1 CELLS; TH2 CELLS; VACCINES, ACELLULAR; WHOOPING COUGH;

EID: 70349296767     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.075     Document Type: Article

References (35)

1. www.cdc.gov. Pertussis-United States; 2001-2003.
2. www.who.int. Immunization, Vaccines and Biologicals: pertussis.
3. Mills K.H.G., Barnard A., Watkins J., and Redhead K. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 61 2 (1993) 399-410
4. Barbic J., Leef M.F., Burns D.L., and Shahin R.D. Role of gamma interferon in natural clearance of Bordetella pertussis infection. Infect Immun 65 12 (1997) 4904-4908
5. Redhead K., Watkins J., Barnard A., and Mills K.H.G. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect Immun 61 8 (1993) 3190-3198
6. Leef M., Elkins K.L., Barbic J., and Shahin R.D. Protective immunity to Bordetella pertussis requires both B cells and CD4+ T cells for key functions other than specific antibody production. J Exp Med 191 11 (2000) 1841-1852
7. Ryan M., Murphy G., Gothefors L., Nilsson L., Storsaeter J., and Mills K.H. Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells. J Infect Dis 175 5 (1997) 1246-1250
8. Mills K.H.G. Immunity to Bordetella pertussis. Microbes Infect 3 8 (2001) 655-677
9. Guiso N., Njamkepo E., Vié le Sage F., Zepp F., Meyer C.U., Abitbol V., et al. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 25 (2007) 1390-1397
10. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., and Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular and a whole-cell pertussis vaccine. N Engl J Med 334 (1996) 349-355
11. Mascart F., Hainaut M., Peltier A., Verscheure V., Levy J., and Locht C. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine 25 (2007) 391-398
12. Ryan M., Murphy G., Ryan E., Nilsson L., Shackley F., Gothefors L., et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 93 (1998) 1-10
13. Ausiello C.M., Urbani F., la Sala A., Lande R., and Cassone A. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect Immun 65 (1997) 2168-2174
14. von König C.H., Halperin S., Riffelmann M., and Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2 (2002) 744-750
15. Di Tommaso A., Bartalini M., Peppoloni S., Podda A., Rappuoli R., and De Magistris M.T. Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long-lasting humoral and cellular responses in adults. Vaccine 15 11 (1997) 1218-1224
16. van der Velden V.H.J., Laan M.P., Baert M.R.M., de Waal Malefyt R., Neijens H.J., and Savelkoul H.F.J. Selective development of a strong Th2 cytokine profile in high-risk children who develop atopy: risk factors and regulatory role of IFN-γ, IL-4 and IL-10. Clin Exp Allergy 31 (2001) 997-1006
17. Storsaeter J., Wolter J., and Locht C. Pertussis vaccines. In: Locht C. (Ed). Bordetella Molecular Microbiology (2007), Horizon Bioscience, Norfolk, U.K. 245-288
18. Antoine R., and Locht C. Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin. Infect Immun 58 6 (1990) 1518-1526
19. Alonso S., Pethe K., Mielcarek N., Raze D., and Locht C. Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during Bordetella pertussis infection. Infect Immun 69 10 (2001) 6038-6043
20. Mascart F., Verscheure V., Malfroot A., Hainaut M., Piérard D., Temerman S., et al. Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses. J Immunol 170 (2003) 1504-1509
21. Esposito S., Agliardi T., Giammanco A., Faldella G., Cascio A., Bosis S., et al. Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection. Infect Immun 69 7 (2001) 4516-4520
22. Hallander H.O., Gustafsson L., Ljungman M., and Storsaeter J. Pertussis antitoxin decay after vaccination with DTPa response to a first booster dose 31/2-61/2 years after the third vaccine dose. Vaccine 23 (2005) 5359-5364
23. Giuliano M., Mastrantonio P., Giammanco A., Piscitelli A., Salmaso S., and Wassilak S.G. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J Pediatr 132 6 (1998) 983-988
24. Ad hoc group for the study of pertussis vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events. Lancet 1988;1(8592):955-60.
25. Gustafsson L., Hessel L., Storsaeter J., and Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3,5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 118 3 (2006) 978-984
26. Barrios C., Brawand P., Berney M., Brandt C., Lambert P.H., and Siegrist C.A. Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting. Eur J Immunol 26 7 (1996) 1489-1496
27. Rowe J., Macaubas C., Monger T.M., Holt B.J., Harvey J., Poolman J.T., et al. Antigen-specific responses to diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized. Infect Immun 68 (2000) 3873-3877
28. Rowe J., Macaubas C., Monger T., Holt B.J., Harvey J., Poolman J.T., et al. Heterogeneity in diphtheria-tetanus-acellular pertussis vaccine-specific cellular immunity during infancy: relationship to variations in the kinetics of postnatal maturation of systemic Th1 function. J Infect Dis 184 (2001) 80-88
29. Upham J.W., Rate A., Rowe J., Kusel M., Sly P.D., and Holt P.G. Dendritic cell immaturity during infancy restricts the capacity to express vaccine-specific T-cell memory. Infect Immun 74 2 (2006) 1106-1112
30. Sallusto F., Lenig D., Förster R., Lipp M., and Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401 (1999) 708-712
31. Beverley PCL. Primer: making sense of T-cell memory. Nature Clin Pract Rheum 4 1 (2008) 43-49
32. Zanetti M., and Franchini G. T cell memory and protective immunity by vaccination: is more better?. Trends Immunol 27 11 (2006) 511-517
33. Fernandez V., Andersson J., Andersson U., and Troye-Blomberg M. Cytokine synthesis analyzed at the single-cell level before and after revaccination with tetanus toxoid. Eur J Immunol 24 8 (1994) 1808-1815
34. Byl B., Gérard M., Libin M., Clumeck N., Goldman M., and Mascart F. Single cell analysis of antigen-specific T cell responses in HIV-infected individuals. Cell Immunol 192 (1999) 107-112
35. Roduit C., Bozzoti P., Mielcarek N., Lambert P.-H., del Giudice G., Locht C., et al. Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis. Infect Immun 70 7 (2002) 3521-3528